Qualitek Lab Limited

[rk1771]

THE COMPANY:
Qualitek Labs, a NABL ISO / IEC 17025 : 2017 accredited laboratory company formed by Industry professionals having more than one decade of experience in the testing, inspection, certification, homologation and audit services. They have state of the art infrastructure facility at Pune, Bhubaneswar, Noida – India, offers innovative leading edge solutions to the automotive, electrical, aerospace and allied industries on testing, homologation, certification and consultancy. The services includes testing, Inspection, Research and Development, Consultancy. They serve various industry like automative, electricals, electronics, foods and drugs, energy, minerals etc.
The company came out with IPO in January, 2024 @ Rs. 100 per share. Later, in the month of August 2024, preferential allotment of around 26 lakhs shares was made to the group of 40 investors at Rs. 198 per share. In this Preferential issue Ashish Kacholia acquired almost 5% of the company.
The company is acquiring a group company ITC Labs Limited for cash consideration of 32 Crores [for 50% shares] and issuing 16 lakhs shares for remaining share swap. The company is also acquiring a software company- Quality and Testing Infosolutions Private Limited for a cash consideration of Rs. 5 Crores.
Presently the company equity stands at 9.98 crores, which will go up to 11.6 crores after shares will be issued to the shareholders of ITC Lab on share swap arrangement. Qualitek is mainly into automative testing (80%) and single digit revenues from water, minerals and defense sector. While ITC Labs is majorly into pharma, cosmetics and food testing. ITC Revenue was 32 crores in FY24, with profit of around 1.5 crores.
ITC Labs is facing a litigation issue. ITC Ltd has filed a case for the name of ITC Labs and defamation of 50 cr. This might lead to long legal battle but the order is on stay in Calcutta HC at the moment and company is allowed to use the name ITC Labs.
At AGM, chairman gave targets of 90 Cr. for FY 25 and 120 Cr. for FY 26 on consolidated basis.

FINANCIALS:
Standalone financials of Qualitek is impressive;

Growth rate has been impressive for last five years;

By the end of this financial year, the company will be able to acquire ITC Labs and shall be reporting consolidated numbers. The management has guided 90 Crores revenue in 2025 and 120 Crores revenue in 2026 on consolidated basis.
H1- 2024-25:
On a standalone basis, qualitek revenue is almost 21 crores, with net profit of 1.7 crores. Margins have been under pressure in H1 as two labs are being created in Noida and Bhuwaneshwar with pre operative expenses. The management has explained the same in the investors presentation.
4b3ba8fd-929c-49c8-af7c-c4f7fef9e390.pdf (3.2 MB)
Management has further reported that in the existing lab in Pune and Bhuwaneshwar, EBIDTA margin has improved by 1% point.
They are expecting revenue from Noida Labs from Q4-2024-25 onwards and Mineral Testing Facility in Bhuwaneshwar from Q1-2025-26 onwards.

Investment Thesis:

1. Industrial testing companies are supposed to have moat and they are able to operate on decent profitability. However, we do not have any listed peer in Indian Stock Market. Comparision with Bureau Veritas is not fair. However, it can be seen that the company, though operating on a very small scale is opearing at 25-30% EBIDTA in the last few years. I expect them to maintain EBITDA around 25%.
2. In a developing economy like India, society is becoming more conscious of health and safety hazards, environment, quality, durability etc. giving a tailwind to testing and inspection companies.
3. With acquisition of ITC labs, software company and various expansion plan; the company is likely to get a scale and operational efficiency. Further, the business looks scalable. Promoters are in this field for last many decades, and they can execute the plans.
4. Though the valuation look stretched as of now, on projected revenue of 120 crores in FY 2026, with 25% EBIDTA; valuation looks okay.
   RISK FACTORS:
5. ITC Labs has lower profitability. The management is expecting to improve its profitability, which they may not do.
6. Valuation looks stretched without much margin of safety.
7. Company has already seen a sharp upside and deep correction cannot be ruled out.
8. The company has ambitious growth plans, and will need huge capital outlays for financing such growth.
9. Micro cap stocks are risky by nature and one can lose 100% of invested capital.

[Disclosure: Invested and Biased]

[karanthharsha999]

One of the reason for IPO is to repay the borrowed money by the promoter.

[Dhvanit_Merchant17]

Yeah it is one of the poor reasons for raising funds.

On the flip side it was given interest free to QLL to help grow the business quickly.

It can be treated more as an OFS then loan repayment as it’s nature was interest-free.

It helped the company on pre-IPO time

A net lose-lose for new investors (post IPO).

[sameernics]

The company seems to be founded in 2018? I think this business has very intense competition. So wondering how are they different from others?

[rk1771]

Yes, specifically Qualitek Lab Limited was incorporated in 2018.
However, the promoters started ITC Lab, a proprietorship, in 1988. They incorporated ITC Labs in 2016. ITC labs is generally into food and pharmaceuticals testing. Qualitek lab is in Industrial testing, which they incorporated in 2018.
After the share swap, ITC Lab will become a 100% subsidiary of qualitek. Present CEO of Qualitek is the CEO of ITC Labs too.
It is true that one of the object of the IPO was loan payment to the promoters. However, I dont see how that is lose-lose proposition for new investors. They could have very well sold their shares and took the money. Of course it is in the nature of OFS.

[Dhvanit_Merchant17]

Coverage of Qualitek Labs by Nuvama under its Emerging Ideas Conference 2024:

QLL Nuvama Ideas 2024.pdf (867.9 KB)

[rk1771]

Qualitek has come out with good results. On an standalone basis revenue is up by 57%. Net profit growth is muted at 23%, due to slightly higher operating cost and finance expenses.
The year has been good for them. They did drinking water sample testing, topographical survey for horticultural development, Milk and milk products testing, EV battery testing, defense testing etc. Bhuwaneshwar lab was established, Noida lab was expanded, Commercial work started in Baddi lab, received various approvals and accreditations. Management is expecting 2X revenue in every 2 years, with 30% EBITDA margin. ITC lab acquisition is likely to be completed in the current financial year.
On an consolidated basis, qualitek and ITC has a topline of 85 crores. Doubling it with 30% EBIDTA by 2026-27 shall result in almost 40 crores net profit (Purely my estimate).
The investor presentation is here, happy reading.
dc5c4a4e-5781-4d29-9e57-2d8d19007a75.pdf (7.4 MB)

[rk1771]

The company has informed the exchange about 10.19 crores from IOCL. They have also acquired a food testing lab in Mumbai.
Qualitek.pdf (200.6 KB)

[rk1771]

Qualitek has come out with steller results. H2 FY26 consolidated Revenue from Operations came in at ₹70.27 Crore, up 56% year-on-year against ₹45.20 Crore in H2 FY25 and 30% sequentially over ₹54.24 Crore in H1 FY26. For the full year, consolidated revenue stood at ₹124.52 Crore, a 77% increase over ₹70.23 Crore in FY25 and a 4x build over the ₹29.18 Crore reported in FY24 — in line with the Company’s stated commitment to double revenue every two years.

H2 FY26 EBITDA was ₹18.05 Crore, more than double the ₹8.90 Crore reported in H2 FY25 and 61% ahead of ₹11.23 Crore in H1 FY26. Full year, EBITDA grew 80% to ₹29.28 Crore from ₹16.25 Crore in FY25, driven by operating leverage on a larger base, a richer mix of pharmaceuticals and food testing revenue, and the early integration benefits at Interstellar. H2 FY26 PAT was ₹9.89 Crore, up 145% over ₹4.00 Crore in H2 FY25 and 107% over ₹4.77 Crore in H1 FY26. Full year PAT grew 91% to ₹14.66 Crore against ₹7.68 Crore in FY25. Gross margin expanded to 87% from 85%, reflecting the asset-light economics of testing services and disciplined management of consumables and direct expenses.

Margins are improving across the base. In H2 FY26, where consolidated EBITDA margin printed at 25.7% and PAT margin at 14.1%; The company expects to touch EBIDTA margin of 30% and PAT margin at 15%. The management is guiding 35-40% growth, in line with doubling revenue every 2 years.

Qualitek Mediarelease.pdf (525.4 KB)

The company is on high growth path, and open to growth through inorganic acquisitions. Further, Testing services (like what Qualitek provides in pharma and auto) are the most scalable and can achieve the highest margins once the lab hits a 60–70% utilization rate. A lab running at 30% capacity might barely break even due to high electricity, calibration, and accreditation maintenance costs. That same lab running at 80% capacity can see profit margins expand explosively because the fixed overheads are already absorbed.

Presently they have 92 crores debt on the books, and paid interest of around 5 crores. Cash flow position of the company is good, and I dont see and problem is servicing the debts. Once the debt is pared, may be after 4-5 years of growth, eps can jump merely through interest saving.

The testing industry is likely to grow @11% in India. Further, stand alone labs finding it difficult to grow on its own, business is moving from unorganized stand alone labs to organized labs, due to stricter regulations on quality. The company is standing at a sweet spot.

They have shared an investor presentation, giving their future plans. Happy reading.

Qualitek Investor Presentation_compressed.pdf (4.8 MB)

[harshit11]

Hi Rajesh, seems like a very interesting company; my only concern is, will it be able to sustain past levels of growth (>50% CAGR) or has it already matured? also, have you had the chance to speak with the management ever?

[rk1771]

In developed economies, the TIC industry typically accounts for approximately 0.3% to 0.5% of the total GDP. To put this into perspective, the global TIC market is currently valued at roughly $250 billion to $265 billion. While it makes up about 0.25% of the global GDP, the concentration is notably higher in developed nations due to stricter regulatory environments and advanced manufacturing bases.

Indian story has just began. Apart from Bureau of Indian Standards, there is no body except stand alone labs here and there. Qualitek is the first private organized player in the space. The market is dominated by global giants like SGS, Bureau Veritas, Eurofins, Intertek, UL solutions.

Indian TIC market is very big, but a large part is internal testing by manufacturers. Third party TIC can be estimated to about 1 lakh crore. In this market, Qualitek topline of 125 crores is a drop in the ocean.

I see Qualitek as benefiting from unorganised to organized shift. Indian TIC market is dominated by stand alone labs, where Qualitek can provide pan India service. There shall be a movement towards organized testing labs - recent acquisitions of Banglore and Mumbai stand alone labs shows that. The management is guiding doubling revenue every 2 years, which looks believable at least in foreseeable future.

Worldwide TIC companies commands EBITDA margin of 30 percent with PAT of 12-14 percent. Management is targetting that figure. They are a bit aggressive in taking debt and inorganic expansion, which I suppose is a good strategy in present case, it is a winner takes it all market.

Industry data from early 2026 indicates that there is a potential market of over 250,000 testing laboratories operating across India. However, only about 8,500 of these are formally NABL-accredited (National Accreditation Board for Testing and Calibration Laboratories). This means that by physical volume, less than 4% of the labs are formally organized and accredited. Over 96% are unorganized, standalone local labs.

The Bureau of Indian Standards (BIS) and other regulatory bodies are aggressively expanding Quality Control Orders (QCOs) across sectors like electronics, furniture, chemicals, and toys. Unorganized labs generally lack the capital and technical expertise to conduct these rigorous, mandated tests.

As manufacturing moves to India (under “Make in India”), international buyers require internationally recognized, accredited testing reports, effectively freezing unorganized labs out of the export supply chain. Because obtaining NABL accreditation requires high capital expenditure (CAPEX) for advanced equipment and strict operational standards, smaller unorganized labs are increasingly being acquired by or losing market share to organized players.